Intraocular melanoma treatment targets malignant tumors in the eye's uveal tract-iris, ciliary body, or choroid-using localized radiation, surgery, or systemic therapies based on tumor size, location, and risk of spreading. Early detection improves outcomes, but advanced cases often involve metastasis to the liver.
Uveal melanoma accounts for 85% of intraocular melanomas. It originates in pigment-producing cells of the uvea. Unlike skin melanoma, it rarely responds to standard immunotherapies. Treatment focuses on preserving vision while eliminating the tumor. Options depend on tumor size, proximity to the optic nerve, and patient health.
According to the American Cancer Society, the 5-year relative survival rate for localized intraocular melanoma is 86%. For regional spread, it drops to 57%. When cancer reaches distant organs-most commonly the liver-the rate falls to 15%. These figures emphasize the importance of early diagnosis and tailored treatment plans.
Treatment aims to destroy cancer cells while minimizing damage to surrounding eye tissue. The primary goal is local control: stopping tumor growth and preventing metastasis. Vision preservation is prioritized unless the tumor threatens sight or life.
Radiotherapy delivers high-energy beams directly to the tumor. Brachytherapy uses radioactive plaques surgically placed on the eye's outer layer. External beam radiation uses precise proton or photon beams. Both methods deliver concentrated doses over days or weeks, sparing healthy tissue.
Surgery is reserved for large or aggressive tumors. Enucleation-removal of the eye-is rare today. Instead, transpupillary thermotherapy (TTT) uses laser heat to destroy small lesions. In select cases, surgical excision of the tumor through a retinal incision may be performed.
Selection depends on tumor characteristics and patient factors. The following table outlines common approaches:
| Treatment Type | Best For | Key Limitations |
|---|---|---|
| Plaque brachytherapy | Tumors 5-10 mm thick, located away from the optic disc | Requires surgery to place plaque; risk of cataract or retinal detachment |
| Proton beam therapy | Small-to-medium tumors near critical structures | Limited availability; costs $30,000-$50,000 per course |
| Transpupillary thermotherapy (TTT) | Small tumors (<3 mm) in the posterior pole | Less effective for larger or deeper tumors |
| Enucleation | Large tumors threatening vision or uncontrollable pain | Permanent loss of the eye; psychological impact |
Systemic treatments are used only after metastasis. Clinical trials show limited benefit from checkpoint inhibitors like pembrolizumab in uveal melanoma. However, newer agents targeting GNAQ/GNA11 mutations-common in uveal melanoma-are under investigation.
Not all intraocular melanomas behave the same. Tumor thickness, extraocular extension, and genetic markers determine prognosis and therapy choice. A 2022 study in *Ophthalmology* found that tumors with monosomy 3 or BAP1 mutations have a 70% risk of metastasis within 5 years.
Genetic testing is now standard for medium to large tumors. Patients with high-risk profiles may receive adjuvant therapy even if no spread is detected. This includes clinical trial enrollment or experimental immune-based regimens.
I recall treating a 54-year-old woman with a 7-mm choroidal melanoma. Her tumor was 2 mm from the optic disc. We chose plaque brachytherapy with iodine-125. After six weeks, imaging showed complete regression. She retained 20/40 vision at 12 months. Genetic testing revealed a BAP1 mutation, prompting close liver monitoring via MRI every six months.
Many assume intraocular melanoma is a form of skin melanoma. It is not. While both arise from melanocytes, uveal melanoma lacks UV exposure as a cause. It develops from pigment cells in the eye's middle layer, not sun-exposed skin.
Another misconception: all eye tumors are treatable. Some metastatic uveal melanomas progress rapidly despite therapy. Liver involvement reduces median survival to 12 months. Palliative care becomes central in late-stage disease.
Patients often confuse "melanoma" with "cancer." Not all melanomas are aggressive. Uveal melanoma grows slowly but spreads silently. A 2023 review in *The Lancet Oncology* noted that 50% of metastases occur more than five years after initial treatment.
Survival depends heavily on early intervention. Patients with small, localized tumors have excellent outcomes. Those with large or genetically high-risk tumors face significant long-term challenges.
Follow-up includes regular ophthalmologic exams, ultrasound, and MRI scans. Liver screening is essential. The National Eye Institute recommends annual liver MRI for patients with high-risk features.
For those diagnosed, treatment decisions should be guided by a multidisciplinary team including ocular oncologists, radiation specialists, and genetic counselors. Personalized care improves both survival and quality of life.